The effects of diet and orlistat on body weight and lipid profiles in high risk Chinese patients with coronary artery disease, obesity and hypercholesterolemia
- PMID: 19221831
- DOI: 10.1007/s11845-009-0291-y
The effects of diet and orlistat on body weight and lipid profiles in high risk Chinese patients with coronary artery disease, obesity and hypercholesterolemia
Abstract
Background: Orlistat is a gastrointestinal lipase inhibitor approved for use in obesity. So far, no evidence has been reported on the use of orlistat in obese patients with coronary artery disease (CAD).
Aim: To investigate the effect of orlistat on body weight and lipid profiles in obese patients with CAD and hypercholesterolemia.
Methods: Thirty non-diabetic patients with CAD, body mass index (BMI) > or = 25 kg/m(2) and low-density lipoprotein cholesterol (LDL-C) > or = 2.6 and < 4.1 mmol/L were put on diet for 12 weeks. Those still having a BMI > or = 25 kg/m(2) received orlistat 120 mg thrice daily for another 24 weeks.
Results: BMI was significantly reduced by 1.7% after 12 weeks of dietary treatment. The 24-week orlistat treatment resulted in further significant reduction in BMI (-2.8%) and LDL-C (-7.0%).
Conclusion: Diet and orlistat treatment significantly reduced BMI and improved LDL-C in obese patients with CAD and hypercholesterolemia.
Similar articles
-
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21. doi: 10.1038/sj.ijo.0801814. Int J Obes Relat Metab Disord. 2001. PMID: 11753595 Clinical Trial.
-
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.Clin Ther. 2003 Apr;25(4):1107-22. doi: 10.1016/s0149-2918(03)80070-x. Clin Ther. 2003. PMID: 12809960 Clinical Trial.
-
Orlistat use in overweight women with mild hypercholesterolemia.Int J Clin Pharmacol Res. 2002;22(3-4):85-8. Int J Clin Pharmacol Res. 2002. PMID: 12837045 Clinical Trial.
-
Orlistat: its current status as an anti-obesity drug.Eur J Pharmacol. 2002 Apr 12;440(2-3):109-17. doi: 10.1016/s0014-2999(02)01422-x. Eur J Pharmacol. 2002. PMID: 12007529 Review.
-
Benefit-risk assessment of orlistat in the treatment of obesity.Drug Saf. 2014 Aug;37(8):597-608. doi: 10.1007/s40264-014-0210-7. Drug Saf. 2014. PMID: 25064699 Review.
Cited by
-
Clinical and economic considerations of antiobesity treatment: a review of orlistat.Clinicoecon Outcomes Res. 2010;2:63-74. doi: 10.2147/ceor.s5101. Epub 2010 Jul 5. Clinicoecon Outcomes Res. 2010. PMID: 21935315 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous